Half Year Results 

Hikma raises revenue guidance

Hikma raises revenue guidance

Hikma Pharmaceutical’s (HIK) injectables business enjoyed a particularly strong first half, with double-digit sales growth buoyed by demand for coronavirus-related products. At the same time, the group’s generics division saw revenues rise by a third to $369m (£280m) – helped by contributions from new launches, and some additional purchasing tied to the virus outbreak. Hikma’s organic sales edged up by 9 per cent to $1.1bn, while operating profits climbed by a more pronounced 15 per cent to $284m.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now